Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol (acetaminophen) is a widely used non-opioid analgesic and antipyretic agent. While its exact mechanism of action is not fully elucidated, it is believed to act primarily in the central nervous system by inhibiting cyclooxygenase (COX) enzymes, particularly COX-2, and potentially interacting with the endogenous cannabinoid system and descending inhibitory serotonergic pathways. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs), it has minimal peripheral anti-inflammatory activity and does not significantly inhibit platelet aggregation. Parcam is a branded generic formulation of paracetamol developed by Rishab Health Care, provided as an injectable for the management of acute pain and fever when oral administration is not feasible.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol.